Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394956 | 0.89 | ATM (0.46) | PDE3BPDE3AP2RX3L3MBTL1KDM4E | |
| SCHEMBL2395477 | 0.86 | LMNA (0.39) | LMNAHDAC1HDAC6 | |
| SCHEMBL2396737 | 0.81 | HDAC1 (0.52) | PDE3BPDE3ALMNAP2RX3HTT | |
| SCHEMBL2394880 | 0.77 | ATM (0.44) | PDE3BPDE3AP2RX3L3MBTL1KDM4E | |
| SCHEMBL2397468 | 0.74 | CHRM1 (0.53) | LMNA | |
| SCHEMBL16341783 | 0.72 | CNR2 (0.63) | LMNAP2RX3 | |
| SCHEMBL2397287 | 0.69 | HDAC1 (0.48) | PDE3BPDE3AP2RX3L3MBTL1KDM4E | |
| SCHEMBL17346999 | 0.68 | LMNA (0.76) | LMNAP2RX3ALDH1A1 | |
| SCHEMBL15519278 | 0.68 | HCRTR1 (0.41) | L3MBTL1 | |
| SCHEMBL10047907 | 0.67 | P2RX3 (0.69) | LMNAP2RX3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252299-B1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8022215-B2 | Fused pyridone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324088-A1 | Fused Pyridone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, CHRM4 | PDE3B 932/4885PDE3A 980/4885LMNA 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.